Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cafedrine→

Cafedrine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58166-83-9
Molecular formula
C18H23N5O3
Molecular weight
357.4 g/mol
Drug class
Sympathomimetic vasopressor component of fixed cafedrine/theodrenaline combination
Mechanism of action
Indirectly and directly increases adrenergic tone and supports blood pressure; clinical effects of the marketed combination arise from cafedrine together with theodrenaline. A separate standalone mechanism or indication should not be inferred from the combination product.
Indications / reported uses
  • Component of the fixed cafedrine/theodrenaline combination used for treatment of acute hypotension, particularly during anaesthesia, in countries where the combination is authorised; not a standalone API indication

Sources: NLM MeSH — Cafedrine · PubMed — Cafedrine theodrenaline hypotension · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cafedrine Environmental Risk Assessment (ERA) (the Cafedrine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.